C-reactive protein-triglyceride-glucose index is an independent predictor of cardiovascular mortality in patients with metabolic syndrome
A new blood marker combining inflammation and insulin resistance better predicts heart disease deaths in people with metabolic syndrome, sharpening risk assessment.
In 10,421 US adults with metabolic syndrome followed for up to 20 years, the novel CRP-triglyceride-glucose composite index (CTI) independently predicted cardiovascular mortality, with the highest quartile conferring a 60% excess risk. This combined inflammation-insulin resistance marker may offer improved risk stratification beyond standard lipid/glucose measures for high-risk cardiometabolic patients.
What the study was
- Study design
- Retrospective cohort study (NHANES database, 1999–2010; mortality follow-up through 2019)
- Population
- US adults with metabolic syndrome (≥3 criteria), aged ≥20 years from NHANES 1999–2010
- Sample size
- 10421
- Category
- Prevention
- Maturity
- Validated
- Journal
- Journal of Clinical Lipidology
Why it surfaced
Large population-based cohort (n=10,421) with long follow-up; CTI is a calculable composite marker with potential for immediate clinical application in MetS risk stratification. Retrospective NHANES design and novel composite index limit causality attribution.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.